Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

ClinicalTrials.gov ID: NCT06533579

Public ClinicalTrials.gov record NCT06533579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

Study identification

NCT ID: NCT06533579
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Vironexis Biotherapeutics Inc.; Industry
Enrollment: 32 participants

Conditions and interventions

Conditions

Interventions

Genetic

Eligibility (public fields only)

Age range: 13 Years to 90 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 29, 2025
Primary completion: May 31, 2027
Completion: Aug 31, 2031
Last update posted: Aug 5, 2026

2025 – 2031

United States locations

U.S. sites: 11
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
Valkyrie Clinical Trials	Los Angeles	California	90067	Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Mayo Clinic, Clinical Trials Referral Office	Jacksonville	Florida	32224	Recruiting
Mayo Clinic, Clinical Trials Referral Office	Rochester	Minnesota	55905	Recruiting
New York Medical College	Valhalla	New York	10595	Recruiting
University of North Carolina at Chapel Hill/ University of North Carolina Medical Center	Chapel Hill	North Carolina	27599	Recruiting
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	Recruiting
Oregon Health & Science University	Portland	Oregon	97239	Recruiting
TriStar BMT	Nashville	Tennessee	37203	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06533579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 5, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06533579 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →